Habyt GmbH, founded in 2017 and headquartered in Berlin, Germany, specializes in community-driven and technologically advanced co-living spaces. The company offers a range of fully furnished private and shared apartments with flexible rental options, catering to diverse living arrangements on a global scale. Habyt's focus is on creating environments that foster connections among residents, facilitated by a digital-first approach that standardizes the housing process for both tenants and landlords. The accommodations include essential amenities such as private bedrooms equipped with desks, wardrobes, and Wi-Fi, along with cleaning services and linens. By prioritizing accessibility and comfort, Habyt aims to provide economical housing solutions for individuals seeking flexible living options.
Pinsalab
Acquisition in 2021
Pinsalab are into production of Pinsa, an Italian artisanal by using wheat, rice and soy flours.
CrateDB is an open-source, multi-model distributed database that combines SQL simplicity with NoSQL scalability. It enables real-time analytics of complex, high-volume data, including IoT and machine data.
DACS Laboratories
Seed Round in 2016
DACS Laboratories GmbH, founded in 2014 and headquartered in Erkrath, Germany, specializes in application software distribution technologies and innovative deployment solutions. The company focuses on business development, project management, high-performance computing, and algorithmic design. Its offerings include data transfer, server management, and IT security services, catering to a diverse range of industries such as high-performance computing centers, large-scale data centers, and video game publishing. Notably, DACS Laboratories developed ROCKIT, a fast game start technology that enhances the gaming experience by providing rapid access akin to streaming services like Netflix. This technology utilizes storage virtualization to accelerate data and application delivery, achieving time-to-start ratios that are significantly faster than traditional download methods.
AlpenPartner
Acquisition in 2015
AlpenPartner is an international trading company based in Germany and China, specializing in the import and export of quality food and non-food brands. The company focuses on establishing German and European brands in the Chinese market by providing a wide array of services. These services include market research and analysis, development of entry strategies, product registration and certification, supply chain management, and sales and marketing support. AlpenPartner aims to assist clients ranging from small businesses to large multinational corporations in successfully entering and thriving in the Chinese market, thereby helping them achieve their business objectives.
PlanetHome
Acquisition in 2015
PlanetHome is a leading German-Austrian real estate service provider specializing in residential property placement and financing. Collaborating closely with banks, insurers, and financial institutions, PlanetHome supplements their services optimally for clients around property needs. Since inception, they have facilitated over 100,000 units with an average lending volume exceeding one billion euros.
Isotopen Technologien München
Acquisition in 2009
ITM Isotopen Technologien München AG is a biotechnology and radiopharmaceutical company based in Garching, Germany, focusing on the development, manufacturing, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for cancer treatment. Established in 2004, ITM has built a robust global supply network and accomplished GMP manufacturing capabilities. The company offers a range of products, including EndolucinBeta, a radiopharmaceutical precursor for targeted radionuclide therapy, as well as radionuclides like 225Ac and 213Bi. Additionally, ITM develops automated systems for synthesizing radiolabeled biomolecules and provides GMP radiolabeling services. With a growing portfolio of innovative treatments and partnerships, ITM aims to enhance patient outcomes and quality of life in oncology, specifically addressing conditions such as neuroendocrine cancers and bone metastases while minimizing side effects.